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The Use of Electrocautery as the Primary Ablation Modality
for Malignant and Benign Airway Obstruction
Momen M. Wahidi, MD, MBA, Mark A. Unroe, MD, Natasha Adlakha, Mathew Beyea, MS,
and Scott L Shofer, MD, PhD
Background: Laser has been the main ablative modality in the
airways, but a growing experience with endobronchial electrocau-
tery suggests a comparable efficacy and safety profile.
Objectives: To evaluate the efficacy and safety of electrocautery as the
primary heat therapy for malignant and benign airway obstruction.
Methods: A retrospective review of all patients undergoing endo-
bronchial electrocautery, alone or in combination with other airway
tools, at Duke University Medical Center between April 2004 and
November 2009. Data on efficacy (luminal patency, symptomatic,
radiographic, or physiologic improvement) and safety (complication
rate) were collected.
Results: Ninety-four patients underwent 117 procedures with endo-
bronchial electrocautery for endobronchial malignant and nonma-
lignant disease. Endoscopic improvement was seen in 94% of cases.
Seventy-one percent of patients reported symptomatic improvement.
Radiographic studies demonstrated luminal improvement in 78% of
patients on chest computed tomography, improved aeration on chest
computed tomography and chest x-ray in 63% and 43% of patients,
respectively. The rate of major complications was 0.8%, whereas
minor complications occurred in 6.8% of cases. There was no
perioperative mortality.
Conclusions: Endobronchial electrocautery is effective and safe
when used as an ablative modality in malignant and benign airway
obstruction and has a comparable profile to laser with the advantage
of lower cost.
Key Words: Bronchoscopy, Interventional pulmonology, Electro-
cautery, Airway obstruction, Lung cancer.
(J Thorac Oncol. 2011;6: 1516–1520)
The use of therapeutic bronchoscopy has increased over thepast two decades.1–3 Therapeutic bronchoscopic interven-
tions aim at the treatment of both malignant and nonmalig-
nant causes of central airway obstruction and include a wide
spectrum of modalities including mechanical debridement,
airway dilatation, ablative therapies, and airway stenting.
Each modality is used alone or in combination with other
tools to achieve the desired effect. Currently available abla-
tive therapies include those with immediate effect: Nd:
yttrium aluminum garnet (YAG) laser, electrocautery, argon
plasma coagulation (APC); and those with delayed effect:
cryotherapy, photodynamic therapy, and brachytherapy.1,2,4
Laser, electrocautery, and APC can be used to directly va-
porize tissue or, more commonly, to coagulate tissue before
mechanical debridement.1,3,5 APC is used effectively in su-
perficial lesions, but the tissue penetration is limited to only
1 to 2 mm.2,6 Laser can attain tissue penetration of up to 10
mm and can be used when deeper tissue penetration is
needed.2,6 Multiple studies have demonstrated the efficacy of
laser in the treatment of central airway obstruction in terms of
symptomatic and radiographic improvement with a low com-
plication rate in experienced hands.2,7–12 Because of the
aforementioned favorable profile, laser became the main
airway ablative modality in the nineties; however, its wide
adoption in clinical practice was fraught with its high cost,
bulky size of machine, and the need for protective eyewear.1
Electrocautery is an alternative heat ablative therapy in
the airway that uses an electrical current to generate heat and
cause tissue destruction. Its advantages over laser are its
lower cost, ease of use, and wide availability in most hospi-
tals. Common devices used with electrocautery include the
snare, knife, blunt probe, and hot forceps. The snare is used
to lasso a lesion at its base, which is useful in pedunculated
airway lesions. Electrocautery knife is used to cut through
tissue and is especially effective in disrupting benign stenotic
webs. The blunt probe is used in direct contact with the lesion
and cause tissue coagulation and destruction. Hot forceps
deliver heat while a biopsy is taken and can be used for
transbronchial or endobronchial biopsy; however, their effec-
tiveness have come into question, and they are not commonly
used.13,14 Figure 1 shows an electrocautery application through
the probe on an endotracheal lesion.
Endobronchial electrocautery has not been studied ex-
tensively, but small series have demonstrated that, similar to
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laser, it can achieve high success rates for the relief of central
airway obstruction with favorable safety profile.15–20
In our institution, we use electrocautery rather than
laser as the first-line heat therapy for central airway obstruc-
tion. In this study, we will review our experience with
electrocautery with focus on its efficacy and safety.
METHODS
Study Design and Patients
We retrospectively reviewed all patients referred to
Duke University Medical Center for central airway obstruc-
tion between April 2004 and November 2009 and selected
those who underwent endobronchial electrocautery. This ret-
rospective analysis was approved by the Duke University
Institutional Review Board. All procedures were performed
under the direction of the Duke University Interventional
Pulmonary Group.
Electrocautery was performed using a device manufac-
tured by ERBE surgical systems (Atlanta, GA). Electrocautery
accessories used included the electrocautery snare, knife, and
monopolar probes (Olympus, Center Valley, PA). Standardized
protocols for appropriate power selection were used in accor-
dance with the manufacturer recommendations. Escalating watt-
age was used as indicated to achieve the desired effect.
FIGURE 1. An electrocautery application through
the probe on an endotracheal lesion: (A) endotra-
cheal polypoid lesion; (B) electrocautery applica-
tion through the probe; and (C) site of tracheal
lesion after electrocautery application.
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Data Collection and Measurements
Pre- and postoperative data, including procedure notes,
clinic visits, pulmonary function tests, and radiographic im-
ages were accessed using the institution’s electronic medical
record and radiology systems. Information was entered into a
password-protected database that was accessed by study per-
sonnel only.
The primary outcomes of the study were patients’ re-
sponse to treatment and rate of complications. Response to the
treatment was determined by four factors. Endoscopic luminal
improvement was evaluated as improved or not improved
according to the bronchoscopy procedure note; an improve-
ment was deemed to occur if there was at least 50% improve-
ment in the bronchial lumen. Patient symptoms were evalu-
ated in postprocedure clinic notes as improved, worsened, or
unchanged. Radiographic data were reviewed when both pre-
and postprocedure studies were available. Radiographic data
were evaluated for improvement in the airway lumen and
improvement in aeration of the targeted lung fields. Spirom-
etry data were reviewed when pre- and postprocedure studies
were available. Improvement was considered to be present if
there was greater than 10% improvement in postprocedure
data. Any perioperative or postoperative complications were
recorded.
RESULTS
Ninety-four patients underwent 117 procedures with
endobronchial electrocautery for airway obstruction. Patients
and diseases characteristics are summarized in Table 1. The
majority of patients had malignancy as the primary indication
for intervention, most frequently a lung cancer primary. The
site of intervention most often involved the trachea or main-
stem bronchi. Presenting symptoms included shortness of
breath (68%), cough (34%), hemoptysis (15%), wheezing
(11%), and constitutional symptoms (10%).
Rigid bronchoscopy was performed in 62% of the
procedures, whereas the rest were performed with flexible
bronchoscopy. The electrocautery probe was used in 78% of
procedures, knife in 15%, and snare in 7%. The average
energy used with electrocautery was 30 Watts, but it is worth
noting that the energy used with electrocautery can vary
significantly based on the manufacturer of the energy source
and accessories. Endobronchial electrocautery was typically
accompanied by additional modalities including balloon di-
lation in 25%, tissue excisions in 60%, and airway stenting in
31% of procedures. Stents used during the procedures were
silicone in 47%, metallic in 35%, and hybrid in 18% of cases.
Table 2 summarizes patients’ outcomes. Endoscopic
improvement was seen in 94% of patients undergoing endo-
bronchial electrocautery. Postoperatively, 71% of patients
reported symptomatic improvement, 13% noted worsening,
and 16% had no change. One month after the procedure, 6%
of the patients had deceased.
Radiographic data were reviewed when available pre-
and postprocedure. Twenty-three patients had chest com-
puted tomography available for comparison, with 78%
demonstrating luminal improvement. Furthermore, 63% of
patients with complete or partial lung collapse demon-
strated improved aeration on postprocedure chest com-
puted tomography. Among patients who only had pre- and
postprocedure chest x-rays, 43% of patients with complete
or partial lung collapse demonstrated improvement, al-








African American 26 (22)
Asian 4 (3)
Disease type
Lung cancer 52 (44)
Extrathoracic cancer 30 (26)
Lung transplant 10 (9)
Nonmalignant disease 25 (21)
Tracheal stenosis 8 (32)
Amyloidosis 6 (24)
Granulation tissue 4 (16)
Papillomatosis 2 (8)
Benign tumor 2 (8)




Mainstem bronchi 60 (38)
Bronchus intermedius 26 (16)
Lobar and higher order bronchi 22 (14)
Lobar bronchi only 27 (17)
n  117 unless noted. Results as number (%).
a n  159, as several patients underwent electrocautery at multiple sites.
TABLE 2. Electrocautery Patient Outcomes
Outcomes Value
Endoscopic improvement 110 (94)
Major complicationa 1 (0.8)




No change 15 (16)
Radiologic data
Improvement on chest CTc 18 (78)
Improvement on chest x-rayd 9 (43)
Spirometrye
Improvement in FEV1  10% 5 (36)
Results as number (%). n  117 unless noted.
a Patient aspirated during anesthesia induction and went into atrial fibrillation.
b n  93.
c n  23.
d n  21.
e n  14.
FEV1, forced expiratory volume in 1 second; CT, computed tomography.
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though a majority of the postoperative films were portable,
making sensitivity poor.
Fourteen patients had spirometry performed both pre
and postoperatively. Improvement in the forced expiratory
volume in 1 second or forced vital capacity of at least 10%
was found in 36% of cases, whereas 50% showed no im-
provement, and worsening occurred in 14%.
There was only one major complication (0.8%). This
occurred when a patient aspirated during anesthesia induction
and subsequently went into atrial fibrillation with rapid ven-
tricular response. There were eight minor complications
(6.8%) including minor bleeding (3), postprocedure broncho-
spasm (2), pneumonia (2), and a chipped tooth (1).
DISCUSSION
Despite the use of endobronchial electrocautery over
the past 25 years for the treatment of central airway obstruc-
tion due to malignant and nonmalignant causes, a relative
paucity of data exists to verify its safety and efficacy, with
much of the data in the form of small case series.
The utilization of endobronchial electrocautery was
first described in 1932 but was used infrequently over the
next half century due to safety concerns.21 There was initial
difficulties with grounding, placing the bronchoscopist at
potential risk for electric shock; however, newer systems
overcame this problem by offering grounded bronchoscopes
and bipolar probes that do not require grounding.1,2,4,18 In
1985, Hooper and Jackson16 described a series of four endo-
bronchial electrocautery cases. Three of these cases were
successful in relieving major airway obstruction, and the
fourth was successful in obtaining a diagnosis. They followed
this up with a more extensive series in 1988 of 18 patients, 13
with malignant disease and five with nonmalignant airways
disease.17 The majority of these patients were treated with
electrocautery snare. They reported good success with the
snare and no complications. An additional case series docu-
menting 17 patients with central airway obstruction from lung
cancer treated with electrocautery was published in 1994.19
Fifteen of these patients had immediate airway improvement,
11 had improvement of the lumen size to 75% of normal, and
eight reported improvement in dyspnea. The safety of endo-
bronchial electrocautery was further evaluated in a prospec-
tive study of 37 patients, which found no major complications
and no mortality.18 In addition to its use in central airway
obstruction, van Boxem et al.20 demonstrated the role of
electrocautery as a curative measure for radiographic occult
lung cancer.
Our study represents the largest collection published to
date of patients who have undergone endobronchial electro-
cautery as the primary ablative therapy for central airway
obstruction. This retrospective study reinforces a very favor-
able efficacy and safety profile with luminal improvement
achieved in 94% of the cases and symptomatic improvement
in 71% of patients. There were few minor and major com-
plications in this series, and the majority of them can be
attributed to bronchoscopy and anesthesia rather than endo-
bronchial electrocautery per se.
This profile compares favorably to laser therapy. Mul-
tiple past studies have demonstrated the efficacy of laser in
the treatment of central airway obstruction.8,11,22 Improve-
ment in symptoms relief has been demonstrated in 63 to 94%
of patients who underwent laser therapy as part of a multi-
modality approach for central airway obstruction, whereas
improvement in lumen has been shown in 83 to 93% of
patients.8,11,22 In the largest series describing the use of laser
in malignant airway obstruction, which included 2610 proce-
dures in 1838 patients, there were a total of 60 complications
associated with the use of laser, leading to 12 deaths.9 The
most common complications included hemorrhage and respi-
ratory failure.
One perceived advantage of electrocautery over laser
therapy is the cost, as both the initial investment in an
endobronchial electrocautery system and the maintenance are
a fraction of the cost of a laser system. Boxem et al.7
published a prospective study attempting to evaluate the
cost-effectiveness of laser versus electrocautery. They found
similar efficacy but higher costs for the laser group. Never-
theless, they were unable to capture the equipment cost, and
the difference was entirely due to the variance in the length of
hospital stay before the procedure. Coulter and Mehta15
presented a prospective case series of 118 patients with
endobronchial obstruction that were evaluated for endobron-
chial electrocautery. Forty percent of these patients were felt
to have lesions amenable to intervention with endobronchial
electrocautery; the remainder underwent intervention with
laser. Eighty-nine percent of the electrocautery interventions
were successful, alleviating the need for Nd:YAG laser ther-
apy and presumably reducing costs.
There are likely several reasons for the significant
growth in the use of laser with only minimal interest in
electrocautery. First, the safety profile of endobronchial elec-
trocautery with some of the earlier equipment for both the
patient and the clinician was questionable.2,16 Advances in
endobronchial electrocautery technology, however, have al-
leviated the previous concerns with safety. Second, there is a
belief that endobronchial electrocautery is not suitable for the
treatment of large central airway masses due to its potential
lower depth of effect as compared with laser. Although, in
some situations with larger lesions, electrocautery may take
longer to complete the procedure, we believe that the out-
comes are equal to that of laser. Third, a concern exists
surrounding the fact that electrocautery is a contact modality,
when compared with the noncontact laser and contact may
theoretically induce more bleeding. This concern has not
been verified in studies on endobronchial electrocautery with
no reported increased incidence of bleeding.
Our study has several limitations including the retro-
spective design that may affect the quality of collected data,
the use of additional modalities in the airways beside elec-
trocautery, the lack of a standardized scale to assess patient
symptoms pre- and postprocedure, and the small number of
radiographic and spirometry data pre- and postprocedure.
Nevertheless, our study represents the largest series on endo-
bronchial electrocautery and continues to build the case for
using it as a major airway ablative modality.
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CONCLUSIONS
Laser and electrocautery represent the major thermal
modalities to treat malignant and nonmalignant causes of
significant central airway obstruction. Laser has been more
widely used over the past two decades, although there are no
data that suggests its superiority in efficacy or safety. A small
body of literature suggests that endobronchial electrocautery
is equally effective and safe as laser with significantly lower
equipment cost. Our study will hopefully add to this literature
and solidify endobronchial electrocautery’s role in therapeu-
tic bronchoscopy. A well-designed, prospective trial compar-
ing laser and electrocautery is needed to further delineate the
appropriate role of each modality in the treatment of central
airway obstruction.
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